NT, pipelines are only as good as the FDA approvals attached to each drug and even then that isnt always enough. TRGT, GTCB and DnDn are just a few examples of either deep pipelines ot fda approval that dont pan out. Ill believe in the pipeline once the drugs are either bought or on the market generating significant revs. But yes, i agree that ambs has a very intriguing pipeline. It is now for the science to prove itself and for management to steer them to revenue sucess.